The Grocery Shelf Battle Is Changing—Who Comes Out Ahead? Store brands are gaining unit share over national labels like McCormick as shoppers seek value, while Kroger and Walmart expand private-label lines to capture margin growth.
Prediction: Netflix Stock Is Going to Soar After Oct. 20 Netflix stock looks incredibly cheap heading into its third-quarter earnings report.
4 Vanguard Funds Worth Buying and Holding for the Next 20 Years Tech and AI have dominated the past several years. The next couple of decades could look a lot different.
Better Cryptocurrency to Buy Now With $1,000: Chainlink vs. XRP One of these coins has a fit with its market, and the other hasn't yet found one.
Schwab's Dividend ETF's Worst Year Since 2012 Was a 5.5% Loss. The Cost Showed Up in the Good Years. Its worst calendar year since 2012 was a loss of around 5.5%. What has that steadiness cost in the good years?
Meet the Only AI Stock I'd Buy Over Nvidia in October ASML is thinking years ahead of the AI industry, ensuring it remains an industry leader well into the 2030s.
1 Reason to Buy Carnival Stock (CCL) in October The leading cruise line operator posted all-time-high metrics across the board in Q3.
3 Surging Cryptocurrencies to Buy Now and Hold for 5 Years or More These three coins are positioned to be valuable crypto infrastructure, and they're all gaining traction.
Alphabet Is the Robotaxi Stock to Buy as Waymo Chases 1 Million Rides a Week The robotaxi leader's just halfway to its year-end target. Does the stock need it to get there?
As GLP-1 Drugs Change How People Eat, Drugmakers Collect and Snack Makers Feel the Squeeze The weight-loss drugs are growing in popularity and altering consumer behavior in significant ways.
Costco Stock Is 14% Below Its Record. History Says Buyers Have Usually Been Rewarded. Past dips in the warehouse club's shares have mostly paid off. Does a better September make this one worth buying?
Grail Stock Hit a 12-Month High After Its FDA Panel Win. But Here's the Risk Investors Shouldn't Ignore. FDA approval will help, as will insurer adoption of Galleri, but the price that they might be willing to pay for the test is also critical.
